Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

at MX-2401 has a good safety profile and very favorable pharmacokinetic and pharmcodymamic properties including a long half-life and efficacy in multiple animal models of infectious diseases, including pneumonia. The features of MX-2401 indicate a highly competitive intravenous agent for treating serious gram positive infections (including the highly publicized resistant bacteria, VRE and MRSA). Activities in the program are currently focused on manufacturing and advancing the program to an IND/CTA for clinical development by late 2009. Advances in manufacturing process development have recently been achieved. We have a $9.3 million investment commitment with Canada Industrial Technologies Office (formerly Technology Partnership's Canada (TPC) program) for the development of this compound.

SB9000 (dinucleotide for Hepatitis B Virus infections): This program was out-licensed to Spring Bank Pharmaceuticals and is currently in pre-clinical development. Spring Bank plans to advance the program into the clinical stage of development in the first quarter of 2010. We have a 1,000,000 convertible preferred share and 50,000 common share ownership position in Spring Bank. Under the terms of a license agreement, MIGENIX can also receive up to US$3.5 million in milestone payments during development of the compound and royalties upon commercialization.

MX-4565 (for neurodegenerative diseases): This pre-clinical program has been supported by a grant from the Michael J. Fox Foundation ("MJFF") awarded to us in June 2007 for research related to Parkinson's and other disease indications. The potential for a second year of funding is under review by MJFF and us. The grant award agreement provides Elan Pharmaceuticals with a limited right to license the technology arising from the MJFF project for certain uses in the field of human disease. Other license discussions for ophthalmologic indications are currently active.

Requisition of Special Shareholder Meeting '/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 13 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced ... Diego campus, as a part of its restructuring program,to ... expenses after the setback on indiplon. Following these reductions,Neurocrine ... great disappointment that we have to make this difficult,decision ...
... ANTONY, GRENOBLE France, December 13 ,STALLERGENES S.A and ... for developing and pharmaceutically producing mites,recombinant allergens(1)., ... Allergens",innovation programme for a recombinant protein treatment for ... is,made up of the recombinant allergens Der p ...
... COLUMBIA, Md., Dec. 13 Martek Biosciences,Corporation announced ... DHA and,ARA license and supply agreement for infant ... Pharmaceutical. Under the terms of the,agreement, Martek will ... IlDong,Foodis infant formula products in South Korea., ...
Cached Biology Technology:Neurocrine Announces Work Force Restructuring 2Neurocrine Announces Work Force Restructuring 3STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens 2STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens 3Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 2Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 3
(Date:4/23/2014)... manufacturers are turning away from using triclosan as an ... health concerns. And now scientists are reporting new evidence ... in the ACS journal Chemical Research in Toxicology ... substance called octylphenol, promoted the growth of human breast ... in mice. , Kyung-Chul Choi and colleagues note that ...
(Date:4/23/2014)... April 2013 EMBO today announced Sophie Martin of ... the 2014 EMBO Gold Medal. The award acknowledges her ... organization and development of the cell. , Martin has ... cellular polarity, in particular the way in which the ... cell division. In the last 11 years, she has ...
(Date:4/23/2014)... is the first cause of dementia and affects some ... has yet been found. One of the reasons for ... mechanisms which cause alterations in nerve transmissions and the ... disease., Researchers from the Institute of Neuroscience at the ... involved in memory consolidation and were able to develop ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... School of Medicine have found that new disease pathways ... 1 Gaucher disease, a rare genetic disorder in which ... liver/spleen enlargement, osteoporosis, bone pain, and increased risk of ... could lead to less expensive and more effective ways ...
... the cure for a fungus and parasite that affects millions ... of Missouri Chemistry Professor John Tanner would be the forensic ... model that could eventually solve the crime. Tanner, who also ... joined forces with Pablo Sobrado, an assistant professor of biochemistry ...
... CHAMPAIGN, Ill. University of Illinois chemists have ... in shoe bombs. It could lead to inexpensive, easy-to-use ... elsewhere. Triacetone triperoxide (TATP) is a high-powered explosive ... bombing attempts. TATP is easy to prepare from readily ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... Simultaneously perform 96 assays on one plate. ... microarray plate with 96 (7mm x 7mm) ... gene expression, or screening analysis studies. Unlike ... fit gasket, eliminating the presence of contaminating ...
... Hyb-Seal slide chambers are vapor-tight adhesive chambers ... adhesive chambers are affixed over a sample on ... one of two ports, and the ports are ... be removed and replaced to allow exchange of ...
... of Use : GeneTraffic is built to ... biological research. GeneTraffic provides visual and computational ... data prior to analysis. , Data ... projects using the MIAME (Minimum Information About ...
Biology Products: